Acurx Pharmaceuticals Stock Price, News & Analysis

Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. According to its SEC filings and public disclosures, the company’s approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that block the active site of the Gram‑positive specific bacterial enzyme DNA polymerase IIIC (pol IIIC). By inhibiting this enzyme, Acurx’s candidates are designed to disrupt bacterial DNA replication and lead to Gram‑positive bacterial cell death.

Core focus and therapeutic targets

Acurx’s research and development pipeline targets Gram‑positive bacteria that global health authorities classify as priority pathogens. Company filings and press releases state that its product candidates are being developed against:

• Clostridioides difficile (C. difficile or CDI)
• Methicillin‑resistant Staphylococcus aureus (MRSA)
• Vancomycin‑resistant Enterococcus (VRE)
• Drug‑resistant Streptococcus pneumoniae (DRSP/PRSP)
• Bacillus anthracis (B. anthracis, anthrax), described as a Bioterrorism Category A Threat‑Level pathogen

These bacterial targets are described in Acurx’s S‑1 registration statements and multiple news releases as priority pathogens identified by the World Health Organization (WHO), the U.S. Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA) in the context of antimicrobial resistance.

Lead program: ibezapolstat for C. difficile infection

The company’s lead antibiotic candidate is ibezapolstat, an orally administered, Gram‑Positive Selective Spectrum (GPSS®) antibacterial. Company disclosures describe ibezapolstat as the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections, with a primary indication of Clostridioides difficile Infection (CDI).

Acurx reports that ibezapolstat has completed a Phase 2 clinical program in CDI, including Phase 2a and Phase 2b segments, and is described in multiple press releases as Phase 3 ready in both the U.S. and the European Union. The company states that ibezapolstat demonstrated clinical efficacy in Phase 2, including high clinical cure rates and an absence of CDI recurrence among patients who achieved clinical cure in the combined Phase 2 trial population, as reported in company communications and scientific publications referenced by Acurx.

According to Acurx, ibezapolstat’s antibacterial spectrum includes C. difficile while sparing other Firmicutes and important Actinobacteria phyla in the gut microbiome. Company‑reported data from its Phase 2 program and preclinical studies indicate that ibezapolstat treatment was associated with eradication of colonic C. difficile, overgrowth of beneficial gut microbiota, and favorable changes in bile acid profiles that are known to correlate with colonization resistance against C. difficile.

Regulatory designations and guidance

The company states that in June 2018, ibezapolstat was designated by the FDA as a Qualified Infectious Disease Product (QIDP) for the treatment of patients with CDI under the Generating New Antibiotic Incentives Now (GAIN) Act. In 2019, the FDA granted Fast Track designation to ibezapolstat for CDI. Acurx also reports that the European Medicines Agency (EMA) has provided positive scientific advice indicating that the clinical, non‑clinical and Chemistry Manufacturing and Controls (CMC) information package supports advancement of the ibezapolstat Phase 3 program and, if successful, supports submission of a Marketing Authorization Application (MAA) in Europe.

Company releases further note that Acurx has received a positive opinion from the EMA’s Paediatric Committee (PDCO) on its Pediatric Investigation Plan (PIP) for ibezapolstat use in children with C. difficile infection. Acurx describes this PDCO opinion as satisfying an EMA requirement prior to initiating Phase 3 clinical trials in the European Union and as part of an integrated regulatory strategy that also includes the U.S. FDA.

Planned Phase 3 program

Acurx has disclosed detailed plans for its ibezapolstat Phase 3 registration program in adult CDI. According to company statements, the planned program consists of two international Phase 3 clinical trials designed as 1:1 randomized, active‑controlled, non‑inferiority studies versus standard‑of‑care vancomycin. The trials are described as including predefined primary and secondary endpoints, a Modified Intent‑To‑Treat (mITT) population of an estimated 450 subjects in the initial Phase 3 trial, and statistical analysis plans aligned with FDA guidance for CDI.

The company states that the primary efficacy analysis is intended to assess ibezapolstat’s ability to achieve clinical cure of CDI after a 10‑day oral treatment course, with additional assessments of sustained clinical cure and recurrence rates. Acurx has indicated that with mutually consistent feedback from both EMA and FDA, it considers itself well positioned to commence its international Phase 3 registration program, subject to obtaining appropriate financing.

Preclinical pipeline and DNA pol IIIC platform

Beyond ibezapolstat, Acurx describes a preclinical pipeline of DNA pol IIIC inhibitor antibiotics aimed at systemic treatment of infections caused by Gram‑positive priority pathogens. Company disclosures refer to the ACX‑375C program, for which Acurx reports having obtained multiple patents in the U.S., Israel, Japan, India and Australia related to DNA polymerase IIIC inhibitors for infections caused by Gram‑positive bacteria, including MRSA, VRE and PRSP, with additional country‑level filings in process.

Acurx reports that its preclinical efforts include development of an oral product candidate for treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI). The company also states that, based on this work, a development program for treatment of inhalational anthrax caused by B. anthracis is being planned in parallel. Public communications further describe research on potential applications in hospital‑ and ventilator‑associated pneumonia and other serious Gram‑positive infections, though these remain at the preclinical and discovery stages according to the company.

In several scientific and corporate updates, Acurx highlights collaborative structural biology research with Leiden University Medical Center (LUMC) in the Netherlands. This collaboration has focused on elucidating the three‑dimensional structure of DNA polymerase C (pol IIIC) from Gram‑positive pathogens in complex with Acurx inhibitors, including ibezapolstat and other lead compounds. The company reports that these studies, published in peer‑reviewed journals, provide mechanistic insights into the mode of action of pol IIIC inhibitors and inform rational design of new compounds.

Microbiome selectivity and class effect

A recurring theme in Acurx’s communications is the potential microbiome‑sparing profile of its DNA pol IIIC inhibitor class. Data presented by the company from Phase 2 ibezapolstat trials and preclinical models suggest that ibezapolstat’s selective activity in the gut spares beneficial bile acid‑metabolizing bacteria. Acurx has reported that this selectivity is associated with favorable bile acid profiles and may contribute to reduced CDI recurrence.

At scientific conferences, Acurx has also presented preclinical data indicating that microbiome selectivity, when compared to comparator antibiotics such as linezolid, may represent a broader class effect of its DNA pol IIIC inhibitor pipeline. The company has stated that these findings support further development of systemic pol IIIC inhibitors for serious infections where preservation of the gut microbiome could be clinically relevant.

Intellectual property and platform technologies

Company press releases describe an expanding intellectual property estate around DNA polymerase IIIC inhibitors. Acurx reports multiple granted patents, including in the United States and several international jurisdictions, covering composition of matter and related aspects of its ACX‑375C program and other pol IIIC‑targeting compounds. The company characterizes these patents as protecting its technologies in the antimicrobial field for an extended period, subject to applicable patent terms and potential extensions.

Acurx also states that it employs AI‑supported drug discovery approaches, referencing the use of Artificial Intelligence and Free Energy Perturbation (FEP) methods to inform chemical synthesis strategies and identify novel DNA polymerase IIIC inhibitors. According to company commentary, these tools are used alongside structural biology data to guide rational design of compounds with desired pharmacological properties and organism specificity.

Corporate and capital markets profile

Acurx Pharmaceuticals, Inc. is incorporated in Delaware and, according to its SEC filings, qualifies as an emerging growth company and a smaller reporting company under U.S. securities regulations. Its common stock trades on the Nasdaq Capital Market under the symbol ACXP. The company has disclosed various capital‑raising activities, including warrant inducement transactions, equity lines of credit and registration statements on Form S‑1 covering resales of common stock by selling stockholders.

In 2025, Acurx reported implementing a 1‑for‑20 reverse stock split of its common stock, with the stated purpose of increasing the per‑share trading price to regain compliance with Nasdaq’s minimum bid price requirement. Subsequent Nasdaq communications reported by the company indicate that Acurx regained compliance with both minimum bid price and minimum stockholders’ equity thresholds, and that its common stock remains listed and traded on the Nasdaq Stock Market.

Collaboration and grant‑funded research

Acurx has highlighted public‑private partnerships and grant‑funded collaborations as part of its R&D strategy. In particular, the company reports multi‑phase collaborative projects with Leiden University Medical Center (LUMC) supported by Health~Holland and related Dutch life sciences initiatives. These projects focus on medium‑throughput biochemical assays for pol IIIC enzymes, structural determination of pol IIIC from various Gram‑positive pathogens, and characterization of Acurx inhibitors at the enzyme target using techniques such as crystallography and cryo‑electron microscopy.

According to Acurx, this work has produced kinetic data across multiple priority pathogens and three complete structures of a representative pol C enzyme in different states, providing structural insights that inform ongoing discovery of systemically active pol IIIC inhibitors.

Risk profile and development stage

As described in its SEC filings, Acurx is a clinical‑stage and late‑stage development company without approved commercial products. Its business is subject to the typical risks of biopharmaceutical development, including clinical, regulatory, manufacturing, financing and market risks. The company’s forward‑looking statements emphasize uncertainties around clinical trial outcomes, regulatory approvals, commercialization prospects and the availability of capital to fund planned studies.

FAQs